66
4
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4140 |
IRAK4-IN-1
|
IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-1 是白细胞介素-1 受体相关激酶 4 抑制剂(IC50:7 nM)。 | |||
T62714 |
IRAK4-IN-20
BAY-1834845 |
IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-20 是一种有效的、具有口服活性的 IRAK4 抑制剂( IC50 : 3.55 nM)。 IRAK4-IN-20 ,具有抗缓解炎症、抗肿瘤和抗癌作用,常用于治疗急性呼吸窘迫综合征 (ARDS) 。 | |||
T5354 |
IRAK4-IN-7
CA-4948 |
IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-7 (CA-4948) 是白介素 1 受体相关激酶 4 (IRAK4) 的选择性抑制剂,口服有活性。它可用于研究癌症以及炎症疾病。 | |||
T11673 |
IRAK4-IN-4
|
IRAK; cGAS | Immunology/Inflammation; NF-κB |
IRAK4-IN-4 (化合物 15) 是白介素-1 受体相关激酶抑制剂,IC50为 2.8 nM。它还抑制环 GMP-AM 合酶 ,IC50为 2.1 nM。 | |||
T39902 |
PROTAC IRAK4 degrader-5
PROTAC IRAK4 degrader-5 |
||
PROTAC IRAK4 degrader-5 is a Cereblon-based IRAK4 degrader. | |||
T39920 |
PROTAC IRAK4 degrader-3
PROTAC IRAK4 degrader-3 |
||
PROTAC IRAK4 degrader-3 is a PROTAC-induced IRAK4 degrader based on von Hippel-Lindau. | |||
T39903 |
PROTAC IRAK4 degrader-6
PROTAC IRAK4 degrader-6 |
||
PROTAC IRAK4 degrader-6 is a potent Cereblon-based compound designed to degrade interleukin-1 receptor-associated kinase 4 (IRAK4). | |||
T39901 |
PROTAC IRAK4 degrader-4
PROTAC IRAK4 degrader-4 |
||
PROTAC IRAK4 degrader-4 (US20190192668A1, compound I-127) is a Cereblon-based PROTAC specifically designed to target and degrade interleukin-1 receptor-associated kinase 4 (IRAK4). | |||
T63388 |
IRAK4-IN-8
|
IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-8 (VI-177) 是一种 IRAK4 抑制剂,可用于研究与癌症和炎症相关的疾病。 | |||
T11674 |
IRAK4-IN-6
|
Others | Others |
IRAK4-IN-6 是一种选择性的、口服有效的IRAK 抑制剂,IC50为 4 nM,靶向 MyD88 L265P 突变型弥漫性大 B 细胞淋巴瘤。 | |||
T24174 | IRAK4-IN-16 | ||
IRAK4-IN-16 (compound 4) 是一种强效的白细胞介素 -1 受体相关激酶 4(IRAK4) 抑制剂,IC50为 2.5 nM。IRAK4-IN-16 对 OCI-LY10、TMD8、Ramos 和 HT 细胞表现出细胞毒性活性,其 IC50分别为 0.2、0.2、0.6 和 2.7 μM。 | |||
T13843 |
PROTAC IRAK4 ligand-1
|
Others | Others |
PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4. | |||
T13842 | PROTAC IRAK4 degrader-1 | Others | Others |
PROTAC IRAK4 degrader-1 is a degrader of PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4). | |||
T62950 | IRAK4-IN-18 | ||
IRAK4-IN-18 是一种白介素 1 受体相关激酶 4 (IRAK4) 的有效抑制剂 (IC50: 15 nM)。IRAK4-IN-18 能够抑制 THP 和 DC 细胞中 LPS 诱导的 IL23 产生,阻断关节炎模型大鼠的关节炎发展。IRAK4-IN-18 可用于研究关节炎疾病。 | |||
T63278 | IRAK4-IN-14 | ||
IRAK4-IN-14 是选择性的、有效的、口服具有活力的 IRAK4 抑制剂 (IC50: 0.003 μM),在大鼠和小鼠中具有出良好的 PK 参数。IRAK4-IN-14 与 Acalabrutinib 联合使用对 MyD88/CD79 双突变体 ABC-DLBCL 表现出协同体外作用。 | |||
T79448 |
IRAK4-IN-26
|
IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-26(Compound 21)是IRAK4的有效抑制剂,IC50值为6.2 nM。该化合物的口服生物利用度达21%,主要用于研究炎症和自身免疫性疾病。 | |||
T74062 | PROTAC IRAK4 degrader-2 | ||
PROTACIRAK4 degrader-2 (Compound 9) 是一种 PROTACIRAK4降解剂,在外周血单个核细胞 (PBMC) 中,降解 IRAK4,DC50为 151 nM。PROTACIRAK4 Degrader-2 在 PBMC 细胞中诱导 IRAK4蛋白水平降低,DC50为 36 nM。PROTACIRAK4 degrader-2 还抑制 PBMC 中多种细胞因子释放。 | |||
T74411 |
PROTAC IRAK4 degrader-7
|
||
PROTACIRAK4 degrader-7 (Compound I-417) 是一种具有口服活性的 PROTACIRAK4降解剂,具有抗肿瘤效果。 | |||
T79097 |
PROTAC IRAK4 degrader-8
|
IRAK | Immunology/Inflammation; NF-κB |
PROTAC-IRAK4分解剂-8(化合物2)是针对IRAK4设计的PROTAC,表现出15.5 nM的IC50值。 | |||
T81378 |
PROTAC IRAK4 ligand-3
|
PROTACs | PROTAC |
PROTACIRAK4 ligand-3 为 PROTACIRAK4 degrader-7 配体,适用于癌症研究领域。 | |||
T63558 | IRAK4-IN-21 | ||
IRAK4-IN-21 是选择性的、口服具有活力的、强效的 IRAK4 抑制剂,能够作用于 IRAK4 (IC50: 5 nM) 和 TAK1 (IC50: 56 nM)。IRAK4-IN-21 对 IL-23 的产生表现出有效的抑制作用,其 IC50值为0.17 μM。IRAK4-IN-21 能够用于研究自身免疫性疾病,如斑块状银屑病和银屑病关节炎。 | |||
T62989 | IRAK4-IN-12 | ||
IRAK4-IN-12 (compound 37) 是一种 IRAK4 的有效抑制剂 (IC50: 0.015 μM),具有细胞 pIRAK4 效力 (IC50: 0.5 μM)。 | |||
T78744 |
IRAK4-IN-24
|
IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-24(compound 16)是IRAK4高效抑制剂,显示高Cl及较低口服生物可用性,适用于炎症与自身免疫性疾病研究。 | |||
T79485 |
IRAK4-IN-27
|
IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-27(Compound 22)为高效选择性IRAK4抑制剂,具IC50值8.7 nM。该化合物能够抑制含MYD88L265P突变的DLBCL细胞系生长并促进其细胞凋亡(apoptosis),适用于弥漫大B细胞淋巴瘤(DLBCL)的研究。 | |||
T62850 |
IRAK4-IN-13
|
||
IRAK4-IN-13 (compound 21) 是一种选择性的、有效的 IRAK4 抑制剂 (IC50: 0.6 nM)。IRAK4-IN-13 具有高代谢清除率,人肝微粒体 (HLM) 固有清除率为 96 μL/min/mg。 | |||
T79337 | IRAK4-IN-28 | IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-28(compound 42)是口服活性的IRAK4抑制剂,具有8.9 nM的IC50值。该化合物对IRAK4的结合亲和力高,Kd值为0.58 nM,适用于炎症和自身免疫性疾病研究。 | |||
T61734 |
IRAK4-IN-9
|
||
IRAK4-IN-9 (compound 73) is a highly potent inhibitor of IRAK4, displaying an impressive IC50 value of 1.5 nM. By blocking MyD88-dependent signaling, IRAK4-IN-9 exhibits promising potential for the investigation of inflammatory diseases, autoimmune diseases, and cancer [1]. | |||
T63315 | IRAK4-IN-19 | ||
IRAK4-IN-19 是白介素 1 受体相关激酶 4 (IRAK4) 的有效抑制剂 (IC50: 4.3 nM)。IRAK4-IN-19 能够阻碍 THP 和 DC 细胞中 LPS 诱导的 IL23 产生,抑制关节炎模型大鼠的关节炎发展。IRAK4-IN-19 能够用于研究关节炎疾病。 | |||
T61767 | IRAK4-IN-17 | ||
IRAK4-IN-17 (Compound 5) is a highly potent inhibitor of IRAK4, exhibiting an impressive IC50 value of 1.3 nM [1]. This compound is particularly valuable for research focused on large B-cell lymphoma (DLBCL) [1]. | |||
T63262 |
IRAK4-IN-15
|
||
IRAK4-IN-15 是选择性的、有效的 IRAK4 抑制剂 (IC50: 0.002 μM),具有良好的人类 PK 预测且具有低内在清除率。IRAK4-IN-15 与 Acalabrutinib 联用对 MyD88/CD79 双突变体 ABC-DLBCL 的表现出强大的协同体外活性。 | |||
T60899 | IRAK4-IN-11 | ||
IRAK4-IN-11 (compound 6) 是 IRAK4的有效抑制剂,IC50值为 0.008 μM。IRAK4-IN-11 表现出细胞 pIRAK4 效力,IC50值为 0.19 μM。 | |||
T63559 | IRAK4-IN-22 | ||
IRAK4-IN-22 是选择性的、口服具有活力的、强效的 IRAK4 抑制剂,能够作用于 IRAK4 (IC50: 3 nM) 和 TAK1 (IC50: 17 nM)。IRAK4-IN-21 对 IL-23 的产生表现出有效的抑制作用,其 IC50值为0.10 μM。IRAK4-IN-21 能够用于研究自身免疫性疾病,如斑块状银屑病和银屑病关节炎。 | |||
T61931 |
IRAK4-IN-10
|
||
IRAK4-IN-10 (compound 75) 是有效的 IRAK4抑制剂(IC50为 1.5 nM),对 MyD88 依赖的信号通路具有阻断作用。IRAK4-IN-10 在炎症性疾病、自身免疫性疾病和癌症中具有研究的潜力。 | |||
T79447 |
IRAK4-IN-25
|
IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-25(化合物38)是口服活性IRAK4抑制剂,具有低清除率(Cl=12 mL/min/kg)和IC50值为7.3 nM。它能抑制促炎细胞因子产生,表现出良好的体外安全性和ADME特性。IRAK4-IN-25主要用于研究炎症和自身免疫性疾病。 | |||
T9631 |
IRAK-4 protein kinase inhibitor 2
|
IRAK | Immunology/Inflammation; NF-κB |
IRAK-4 protein kinase inhibitor 2 是有效的白介素 1 受体相关激酶 4 抑制剂,IC50为 4 μM。它在与炎症和免疫相关的疾病领域有研究价值。 | |||
T14367 |
AZ1495
|
IRAK; CDK; Haspin Kinase | Cell Cycle/Checkpoint; Immunology/Inflammation; NF-κB |
AZ1495 是一种口服有活性的白介素-1受体相关激酶 4(IRAK4)抑制剂,能够作用于 IRAK4 (IC50:5 nM)和 IRAK1 (IC50:23 nM)。可用于研究突变型 MYD88L265P 弥漫性 B 细胞淋巴瘤 (DLBCL) 。 | |||
T9381 |
Thalidomide 5-fluoride
2-(2,6-二氧代 - 哌啶-3-基)-5-氟 - 异吲哚-1,3-二酮,H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-5-fluoro- |
Ligand for E3 Ligase | PROTAC |
Thalidomide 5-fluoride (H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-5-fluoro-) 是一种基于沙利度胺的 Cereblon 配体,通过 linker 与 IRAK4 蛋白配体结合形成 PROTACIRAK4 degrader-1。 | |||
T37076 |
Zabedosertib
BAY 1834845 |
IRAK | Immunology/Inflammation; NF-κB |
Zabedosertib (BAY 1834845) 是一种 IRAK4 抑制剂,具有免疫调节潜能。最新研究表明,Zabedosertib 可预防急性呼吸窘迫综合征 | |||
T2457 |
IRAK-1-4 Inhibitor I
IRAK-1/4 Inhibitor I,IRAK-1/4 Inhibitor |
IRAK | Immunology/Inflammation; NF-κB |
IRAK-1-4 Inhibitor I 是一种IRAK1/4双重抑制剂,其IC50分别为 0.2 μM 和 0.3 μM。 | |||
T37082 |
HS271
|
IRAK | Immunology/Inflammation; NF-κB |
HS271 是一个选择性的、口服有效的 IRAK4 抑制剂 (IC50= 7.2 μM)。HS271 表现出优越的体外酶活性和细胞活性以及药代动力学特征。 | |||
TQ0167 |
Zimlovisertib
PF-06650833,PF06650833 |
IRAK | Immunology/Inflammation; NF-κB |
Zimlovisertib (PF-06650833) 是口服有活性的、可生物利用的白介素-1 受体相关激酶 4 (IRAK4) 选择性抑制剂,其IC50=0.2 nM,在 PBMC 分析中,IC50=2.4 nM。它具有研究类淋巴瘤、风湿性关节炎、狼疮等疾病的潜力。 | |||
T9027 |
CA-4948
Emavusertib |
IRAK; FLT | Angiogenesis; Immunology/Inflammation; NF-κB; Tyrosine Kinase/Adaptors |
CA-4948 (Emavusertib) 是一种IRAK4抑制剂,也是一种FLT3抑制剂,具有抗肿瘤作用。 | |||
T75113 |
GLPG2534
GLPG-2534 |
IRAK | Immunology/Inflammation; NF-κB |
GLPG2534 是一种具有口服活性、选择性和有效性的 IRAK4 抑制剂,具有抗炎活性。GLPG2534 对人和小鼠 IRAK4 具有抑制作用,可用于研究银屑病和特应性皮炎。 | |||
T9470 |
HPK1-IN-7
|
MAPK | MAPK |
HPK1-IN-7 是一种口服有活性的、有效的HPK1(造血祖细胞激酶1, MAP4K1) 抑制剂,其IC50值为2.6 nM,具有强大的家族及激酶组选择性。它对 IRAK4 (59 nM) 和 GLK (140 nM) 具有选择性。当它与抗 PD1联合使用时,对 MC38 同基因肿瘤模型表现出极大的疗效。 | |||
T7755 |
Thalidomide 4-fluoride
E3 ligase Ligand 4,2-(2,6-二氧代-哌啶-3-基)-4-氟基-异吲哚-1,3-二酮 |
IRAK; Ligand for E3 Ligase | Immunology/Inflammation; NF-κB; PROTAC |
Thalidomide 4-fluoride (E3 ligase Ligand 4) 是一种基于 Thalidomide 的 Cereblon 配体,可用于募集 CRBN 蛋白。它能够利用 linker 与 IRAK4 靶蛋白配体连接,得到 PROTAC IRAK4 degrader-1。 | |||
T9203 |
JH-X-119-01
|
IRAK | Immunology/Inflammation; NF-κB |
JH-X-119-01 是白介素 1 受体相关激酶 1 的选择性抑制剂。它能够改善 LPS 诱导的小鼠败血症。它可以抑制 IRAK1(IC50:9 nM),在浓度达到 10 μM 时,也不会对 IRAK4 产生抑制作用。 | |||
T5110 |
IRAK inhibitor 6
|
IRAK | Immunology/Inflammation; NF-κB |
IRAK inhibitor 6 是白细胞介素-1受体相关激酶-4的抑制剂(IC50:160 nM)。 | |||
T4299 |
AS-2444697
|
IRAK | Immunology/Inflammation; NF-κB |
AS2444697 是一种口服有效的IRAK-4抑制剂,IC50为 21 nM。它对人和大鼠 IRAK-4 活性具有抑制作用。它通过抗炎作用表现出肾脏保护作用。 | |||
T11559 |
HG-12-6
|
Others | Others |
HG-12-6 is a type II inhibitor of IRAK4. HG-12-6 shows preferential binding to unphosphorylated inactive IRAK4 (IC50: 165 nM). HG-12-6 can modulate IRAK4 activity in autoimmunity and inflammation. | |||
T39248 |
PF-06426779
|
||
PF-06426779 is a potent and selective inhibitor of interleukin 1 receptor associated kinase 4 (IRAK4) , with an IC 50 of 0.3 nM. |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04483 |
IRAK4 Protein, Human, Recombinant (His)
IPD1,NY-REN-64,REN64,interleukin-1 recepto... |
Human | Baculovirus Insect Cells |
Interleukin-1 receptor-associated kinase 4, also known as Renal carcinoma antigen NY-REN-64, IRAK-4, and IRAK4, is a member of the protein kinase superfamily, TKL Ser/Thr protein kinase family, and Pelle subfamily. IRAK4 contains one death domain and one protein kinase domain. IRAK4 is required for the efficient recruitment of IRAK1 to the IL-1 receptor complex following IL-1 engagement, triggering intracellular signaling cascades leading to transcriptional up-regulation and mRNA stabilization. ... | |||
TMPH-02738 |
IRAK3 Protein, Mouse, Recombinant (His & Myc)
|
Mouse | Baculovirus Insect Cells |
Putative inactive protein kinase which regulates signaling downstream of immune receptors including IL1R and Toll-like receptors. Inhibits dissociation of IRAK1 and IRAK4 from the Toll-like receptor signaling complex by either inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor complex. Upon IL33-induced lung inflammation, positively regulates expression of IL6, CSF3, CXCL2 and CCL5 mRNAs in dendritic cells. IRAK3 Protein, Mouse, Recombinant (His & Myc) is expressed in ... | |||
TMPH-02211 |
TLR7 Protein, Human, Recombinant (His & Myc)
|
Human | E. coli |
Endosomal receptor that plays a key role in innate and adaptive immunity. Controls host immune response against pathogens through recognition of uridine-containing single strand RNAs (ssRNAs) of viral origin or guanosine analogs. Upon binding to agonists, undergoes dimerization that brings TIR domains from the two molecules into direct contact, leading to the recruitment of TIR-containing downstream adapter MYD88 through homotypic interaction. In turn, the Myddosome signaling complex is formed i... | |||
TMPH-02212 |
TLR8 Protein, Human, Recombinant (His)
|
Human | P. pastoris (Yeast) |
Endosomal receptor that plays a key role in innate and adaptive immunity. Controls host immune response against pathogens through recognition of RNA degradation products specific to microorganisms that are initially processed by RNASET2. Recognizes GU-rich single-stranded RNA (GU-rich RNA) derived from SARS-CoV-2, SARS-CoV-1 and HIV-1 viruses. Upon binding to agonists, undergoes dimerization that brings TIR domains from the two molecules into direct contact, leading to the recruitment of TIR-con... |